Key facts
- Patho Care’s last known valuation is $500.0M (Jul 2025).
- Notable investors include Hamershlag Private.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Patho Care
- ·The full record, as it builds
Funding rounds
No funding rounds for Patho Care are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Patho Care
Developer of a spectroscopy-based testing platform designed to provide rapid, non-invasive, and cost-effective diagnostic tests for respiratory infections. The company's platform offers mobile and reusable point-of-care testing devices with adaptive artificial intelligence, enabling healthcare providers to diagnose respiratory infections more efficiently and reduce reliance on traditional chemical-based processes.
- Sector
- Healthcare
- HQ
- Rolling Hills Estates, CA, United States
- Founded
- 2020
- Ownership
- Privately Held (backing)
Patho Care doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Patho Care shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Patho Care in its N-PORT filings yet. We sweep new filings monthly.